Category:

Energy and Global Fundamentals Make a Good Case for Owning Western Uranium Stocks

Posted on by Admin


Global Events Seem to have created a Separate Uranium Market for the East and West – Is this an Opportunity?

 

Should investors buy the uranium dip? After reaching a recent high on April 13, spot uranium has come under significant selling pressure. This may be a temporary reaction to lockdowns and restrictions in China related to the country’s zero Covid policy and recent outbreaks. Public companies related to uranium production had reached their highest level since November in April; they have fallen with the price per tonne of the yellow metal.

 

Market Fundamentals

The price for anything goes up and down on two factors, supply and demand – part of demand is speculation. This component of demand is particularly relevant in commodities. Uranium, of course, is a commodity.

Prior to the late April dip, uranium and related companies were experiencing a substantial run-up. The reasons for this were many; in fact, let’s word this are many, because they still exist.

A list worth sharing of reasons to be bullish on uranium was provided on April 20 at NobleCon18 by Peninsula Energy (PENMF). Peninsula is an advanced stage uranium developer, “ready to put pounds in the can, and out to market.” Wayne Heili, who has 30 years of experience in the business, discussed the unfolding trends that explain the enthusiasm for uranium.

 


Corporations involved in uranium production to serve the West followed the price of uranium. The question investors are asking is, does the cheaper entry price create a buying opportunity.

 

The Case for Uranium

Mr. Heili said nuclear is part of the green energy mix that the world is requiring. This mix, the Peninsula CEO pointed out, is splitting into an Eastern and Western-oriented market in terms of who is served. It was explained to the investors present that whether by law or by choice, the utilities that are serving the West are going to stop relying on nuclear fuel from Russia. Western markets are currently characterized as having a supply deficit. There is little or no production, conversion, or enrichment and perhaps not enough fuel fabrication capacity. This, of course, translates into the West needing to create or add capacity to fill the void of not accepting supplies from the East.

We’re now in the part of the nuclear fuel cycle where production will have to be ramped up. Adding to the need is the European Union now recognizes and characterizes uranium as green.

Another catalyst for increased demand and prices is the Sprott Uranium Fund. The investment company’s physical uranium trust is inventorying U308. Material that may never make it to a plant.

The industry has been receiving bi-partisan support from Washington, and national self-reliance has shown its importance when it comes to the supply of energy and other essentials.

Separately at NobleCon18, Mark Chalmers of Energy Fuels (UUUU) spoke about the uranium market and his company. He shared that 20% of electricity produced in the US is from nuclear. The focus on reducing carbon and maintaining or increasing baseload energy has brought about a nuclear renaissance.

Take-Away

While the overall stock market has been trending down this year, energy stocks, including uranium, have been marching much higher. Two weeks ago, Covid fears overseas brought uranium and uranium stocks down to just above their opening at the start of 2022. Is this substantial dip just a blip before they head back up? The energy industry and the uranium sector of that industry are faced with increasing demand. Supplying that demand should increase revenues.

 

Suggested Content



The Good News and Bad News Surrounding US Uranium Self-Reliance

There Seems to be a Perfect Storm in Favor of Uranium Investors





This Firm Facilitates Direct Investment in Physical Uranium

NobleCon18 Peninsula Energy Ltd. Presentation

 

Stay up to date. Follow us:

 

Are labor Strained Industries Allowing More Corporate Control of Employees?

Posted on by Admin 


Image Credit: Yuki kawagishi (Flickr)


‘Great Resignation’ Appears to be Hastening the Exodus of US and Other Western Companies from Russia

 

Companies across the globe are fleeing Russia in an unprecedented display of corporate solidarity with their governments, appalled over the invasion of Ukraine. Over 750 multinational businesses so far have said they’re curtailing, suspending or severing ties to Russia, more than triple the number that abandoned South Africa over apartheid in the 1980s.

Many corporate statements announcing the decisions have emphasized humanitarian aspects and unity with the Ukrainian people. For example, Pepsi suspended soda sales in Russia, describing events in Ukraine as “horrific”; Ford Motor Co. cited Russia’s “threats to peace and stability” in pausing operations at its three plants in the country; and Ikea closed its stores there and called the war a “human tragedy.”

 

This article was republished with permission from The Conversation, a news site dedicated to sharing ideas from academic experts. It was written by and represents the research-based opinions of Steven Kreft, Clinical Professor of Business Economics and Public Policy, Indiana University, Elham Mafi-Kreft, Clinical Associate Professor of Business Economics, Indiana University.

 

Detractors of this type of corporate do-goodery have dismissed it as “virtue signaling,” implying there is an ulterior motive to the grandstanding. As scholars of corporate social responsibility, we believe altruism can play a role in corporate decisions like these, but – as virtual signaling suggests – other more profit-focused drivers are usually at work, especially given the stakes when deciding to abandon an entire country.

In this case, the common theme we see for many companies is the “great resignation” – and the fight to attract increasingly picky, younger Gen Z and millennial workers, who say they want to work for socially responsible brands.


Pepsi, which has been in Russia for over 60 years, suspended soda sales, calling the invasion ‘horrific.’  Image Credit: Alexander Zemlianichenko


A Weighty Decision

A company’s decision to entirely sever its operations in a country is seldom taken lightly.

In leaving Russia, companies will incur significant costs from abandoning equipment, stores and factories, or even an entire workforce. For example, Exxon said it expected to lose US$4 billion in assets over its decision to exit Russia, while McDonald’s restaurant closures will cost the company $50 million per month.

And there’s no knowing when the companies leaving Russia will be able to return – if ever.

Yet that isn’t stopping hundreds of companies from making the difficult decision to back away. Amid their condemnations of the invasion and expressions of solidarity with the Ukrainian people, many companies have also acknowledged clear business-related reasons. Appliance maker Whirlpool cited the security of its workers, Japanese automaker Toyota blamed logistical and supply-chain hurdles, and video streaming company Netflix said troubles with payment processing will strain operations.


Growing Power of Workers

While these practical reasons, along with the moral concerns, could be enough to drive the exodus, we believe the great resignation, in which record numbers of workers are quitting their jobs, is amplifying all these other risks of staying in Russia.

Roughly 47 million U.S. workers voluntarily left their jobs in 2021, accounting for well over a quarter of the civilian labor force, according to the Bureau of Labor Statistics. Over 4.5 million quit in November alone, a single-month record, and nearly that many continued to hand in their notices in early 2022.

It’s not just a U.S. phenomenon. Many other countries are experiencing similarly high rates of workers voluntarily quitting their jobs.

This trend has shifted bargaining power to employees, and companies are struggling to acquire skilled workers to fill vacant positions. Employees are demanding higher pay and more benefits, and some are rethinking their careers so that their work is more aligned with their values.

Another sign of the shift in power is the recent success of youth-led labor organizing efforts. A growing number of Starbucks locations are becoming unionized, while Amazon got its first U.S.-based union after workers on Staten Island in New York City voted to form one in April 2022. Starbucks and Amazon have both suspended operations in Russia.

Some industries are experiencing especially high employee attrition rates, including management consulting and oil and gas, according to a recent article in MIT Sloan Management Review. The attrition rate measures how many workers are lost and not replaced over a period of time.

Management consulting, in which a talented workforce is vital, for example, saw an attrition rate of 16% over the six-month period researchers looked at, or over five times the national average.


Employees Demand Solidarity with Ukraine

This is why it wasn’t a surprise to us that companies in these labor-strained industries either were among those that severed ties with Russia or quickly did so after facing criticism from employees.

IT consultant Accenture, with nearly 700,000 employees, seemed to set the tone for what would be expected of companies in its industry when on March 3, 2022, it said it was discontinuing all business in Russia.

“Accenture stands with the people of Ukraine and the governments, companies and individuals around the world calling for the immediate end to the unlawful and horrific attack on the people of Ukraine and their freedom,” it wrote.

Competitors McKinsey and Boston Consulting Group initially planned more timid withdrawals by cutting ties with the Russian government but continuing to honor existing private contracts. But after current and former employees of both companies took to social media to call out their perceived soft stance and even cowardice on Russia, the companies quickly reversed course by announcing they were pulling out completely. All the other consulting giants have done the same, including Bain, Deloitte, EY, KPMG and PwC.

The big Western oil companies have similarly faced employee pressure to exit Russia, with workers going so far as to refuse to offload Russian oil and gas onto their docks. This comes on top of governments pushing companies to take steps that go beyond the sanctions. In severing ties, companies such as BP, Shell and Exxon have abandoned significant assets in Russia, which will result in huge losses on their balance sheets.

 

Short-Term Costs for Long-term Gains

But accepting these short-term losses appear to be worth it to avoid larger ones down the road.

Recruiting and retaining a talented workforce is an important driver of a company’s long-term profitability.

Training new workers is costly, and the best talent is always hard to recruit – a challenge made worse by the great resignation. Survey after survey has shown workers are increasingly driven by a sense of purpose and expect their companies to reinforce their values.

No company that we know of explicitly cited issues related to the great resignation as a driver of its decision to leave Russia. And industries with high attrition rates and vocal workforces such as Big Tech haven’t seen complete withdrawals. In some cases, such as with Apple, Alphabet and Meta, they’ve suspended some operations but are trying to keep doing business in part because they play important roles in providing free information to Russian citizens to counter Kremlin propaganda.

Every company and every industry has its own unique analysis to go through based on exposure to business and reputational risk in Russia. We believe the great resignation compounds this risk, in some cases significantly. And employees are increasingly reporting feeling stressed out over Ukraine.

Russia’s aggression against Ukraine has been condemned almost universally in the West. Given that, many of the companies that severed ties – while sacrificing short-term profits – likely knew that staying would have been far more harmful for their brand, not only with customers but their employees as well.

 

Suggested Reading



Challenges to the US Dollar as a Reserve Currency and Market Impact

The Risky Position Elon Musk is Placing Himself In





Jack Dorsey, Corporate Boards, and Bad Apples

ESG Policies and Corporate Departures from Russia

 

Stay up to date. Follow us:

 

Aurania Resources (AUIAF)(ARU:CA) – Exploration Focuses on Three Main Target Areas

Posted on by Admin

Tuesday, April 26, 2022

Aurania Resources (AUIAF)(ARU:CA)
Exploration Focuses on Three Main Target Areas

As of April 24, 2020, Noble Capital Markets research on Aurania Resources is published under ticker symbols (AUIAF and ARU:CA). The price target is in USD and based on ticker symbol AUIAF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.

Aurania Resources Ltd. is a Canada-based junior mining exploration company engaged in the identification, evaluation, acquisition, and exploration of mineral property interests, with a focus on precious metals and copper. Its flagship asset, The Lost Cities-Cutucu Project, is in southeastern Ecuador in the Province of Morona-Santiago. The company also has several minor projects in Switzerland.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Focused exploration strategy. Following an internal review of its projects, target types, and funding strategies, Aurania announced in February that it would focus its resources on the exploration of its core mineral concessions in Ecuador, including epithermal gold and porphyry copper targets. The company is exploring joint ventures and partnerships to advance non-core mineral concessions that include sediment-hosted copper-silver and carbonate replacement silver-zinc-lead targets.

    Priorities in 2022.  Exploration will support the refinement of drilling plans for the Awacha porphyry copper target, and Kuri-Yawi B1 and Kuripan epithermal gold-silver targets. We anticipate drilling could begin at Awacha in the first quarter of next year. Recall that an access agreement was signed with the communities around the Awacha porphyry copper target area in January. Geophysics work has …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Lineage Cell Therapeutics (LCTX) – New Program Added To The Development Pipeline

Posted on by Admin

Tuesday, April 26, 2022

Lineage Cell Therapeutics (LCTX)
New Program Added To The Development Pipeline

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Photoreceptor Development Program Announced.  Lineage Cell announced a new program to develop photoreceptor cells for transplantation. This is an additional application of Lineage’s proprietary cell-based technology for growing pluripotent cells into differentiated cells that can be transplanted to repair areas where cells have been lost to disease. The new program will develop cell transplants for the rod and cone photoreceptor cells in the eye.

    Photoreceptor Program Fits With OpRegen.  Lineage Cell’s most advanced product is OpRegen, a retinal pigmented epithelial (RPE) cell transplant therapy for age-related macular degeneration (dry AMD). The new photoreceptor program will develop cells to repair a different type of cell in the retina. The photoreceptor cell transplants have potential to address conditions such as retinitis pigmentosa …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

The GEO Group Inc. (GEO) – NobleCon 18 Presentation Notes

Posted on by Admin

Tuesday, April 26, 2022

The GEO Group, Inc. (GEO)
NobleCon 18 Presentation Notes

With over 94,000 beds owned, leased or managed across its business lines and serving over 260,000 people daily, GEO is a leading provider of mission critical real estate to its governmental partners. The Company is the first fully integrated equity REIT specializing in the design, financing, development, and operation of secure facilities, processing centers, and community reentry centers in the U.S., Australia, South Africa, and the U.K.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    NobleCon 18. GEO CFO Brian Evans presented at NobleCon 18. The Company highlighted its leading market position, dependable cash flows, and potential market opportunity.

    Title 42.  Government officials continue to give credence to a projected massive surge once Title 42 is lifted. Most recently, ICE said it is expecting a “historic” surge in migration at the border. In an April 8th court filing, the agency stated, “ICE is preparing to…respond to an historic border surge, with projections forecasted to triple current arrivals.” …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Release – Travelzoo Reports First Quarter 2022 Results

Posted on by Admin

 

 


Travelzoo Reports First Quarter 2022 Results

Research, News, and Market Data on Travelzoo

 

Travelzoo® (NASDAQ: TZOO):

  • Consolidated revenue of 
    $18.5 million, up 29% year-over-year
  • Non-GAAP consolidated operating profit of 
    $2.7 million
  • Earnings per share (EPS) of 
    $0.19 attributable to 
    Travelzoo from continuing operations

Travelzoo, a global Internet media company that provides exclusive offers and experiences for members, today announced financial results for the first quarter ended 
March 31, 2022. Consolidated revenue was 
$18.5 million, up 29% from 
$14.3 million year-over-year. 
Travelzoo’s reported revenue consists of advertising revenues and commissions, derived from and generated in connection with purchases made by 
Travelzoo members.

The reported net income attributable to 
Travelzoo from continuing operations was 
$2.4 million for Q1 2022. At the consolidated level, including minority interests, the reported net income from continuing operations was 
$2.4 million. EPS from continuing operations was 
$0.19, compared to (
$0.14) in the prior-year period.

Non-GAAP operating profit was 
$2.7 million. The calculation of non-GAAP operating profit excludes amortization of intangibles (
$0.2 million) and stock option expenses (
$0.5 million). See section “Non-GAAP Financial Measures” below.

“We see continued improvement in our business. We seize the exceptional industry opportunities for providing 30 million 
Travelzoo members exclusive and irresistible travel, entertainment, and local offers and experiences. 
Travelzoo members are affluent, active, and open to new experiences. 84% say 
Travelzoo influences their travel destinations because they trust 
Travelzoo“, said  Holger Bartel, Global CEO.

Cash Position
As of 
March 31, 2022, consolidated cash, cash equivalents and restricted cash were 
$36.7 million. Net cash used in operations was 
$6.8 million. Cash was used primarily in connection with a decrease of merchant payables by 
$8.0 million. The Company also used cash of 
$1.0 million to acquire intangible assets in Q1 2022.

Reserve
Reported revenues include a reserve of 
$3.8 million related to commissions to be earned from vouchers sold. The reserve is booked as contra revenue.

Travelzoo North America

North America business segment revenue increased 19% year-over-year to 
$11.7 million. Operating profit for Q1 2022 was 
$1.7 million, or 15% of revenue, compared to an operating profit of 
$39,000 in the prior-year period.

Travelzoo Europe

Europe business segment revenue increased 66% year-over-year to 
$5.9 million. Operating profit for Q1 2022 was 
$178,000, or 3% of revenue, compared to an operating loss of 
$696,000 in the prior-year period.

Jack’s Flight Club
On 
January 13, 2020, 
Travelzoo acquired 60% of 
Jack’s Flight Club, a membership subscription service. 
Jack’s Flight Club revenue decreased 7% year-over-year to 
$823,000. Non-GAAP operating profit for Q1 2022 was 
$249,000, compared to a non-GAAP operating profit of 
$174,000 in the prior-year period. After consolidation with 
Travelzoo, 
Jack’s Flight Club’s net income was 
$11,000, with 
$7,000 attributable to 
Travelzoo as a result of recording 
$226,000 of amortization of intangible assets related to the acquisition.

Licensing
In 
June 2020, 
Travelzoo entered into a royalty-bearing licensing agreement with a local licensee in 
Japan for the exclusive use of 
Travelzoo’s brand, business model, and members in 
Japan. In August of 2020, 
Travelzoo entered into a royalty-bearing licensing agreement with a local licensee in 
Australia for the exclusive use of 
Travelzoo’s brand, business models, and members in 
Australia, 
New Zealand, and 
Singapore. Under these arrangements, 
Travelzoo’s existing members in 
Australia, 
Japan, 
New Zealand, and 
Singapore will continue to be owned by 
Travelzoo as the licensor. Licensing revenue is booked with a lag of one quarter. 
Travelzoo recorded 
$9,000 in licensing revenue from the licensee in 
Japan in Q1 2021. 
Travelzoo recorded 
$7,000 in licensing revenue from the licensee in 
Australia, 
New Zealand, and 
Singapore in Q1 2022. Licensing revenue is expected to increase going forward.

Members and Subscribers
As of 
March 31, 2022, we had 30.7 million members worldwide. In 
North America, the unduplicated number of 
Travelzoo members was 16.7 million as of 
March 31, 2022, down 8% from 
March 31, 2021. In 
Europe, the unduplicated number of 
Travelzoo members was 9.1 million as of 
March 31, 2022, up 5% from 
March 31, 2021. 
Jack’s Flight Club had 1.7 million subscribers as of 
March 31, 2022, up 6% from 
March 31, 2021.

Discontinued Operations
As announced in a press release on 
March 10, 2020, 
Travelzoo decided to exit its 
Asia Pacific business and operate it as a licensing business going forward. Consequently, the 
Asia Pacific business has been classified as discontinued operations since 
March 31, 2020. Prior periods have been reclassified to conform with the current presentation. Certain reclassifications have been made for current and prior periods between the continued operations and the discontinued operations in accordance with 
U.S. GAAP.

Income Taxes
Income tax expense was 
$968,000 in Q1 2022, compared to an income tax expense of 
$742,000 in the prior-year period.

Non-GAAP Financial Measures
Management calculates non-GAAP operating income when evaluating the financial performance of the business. 
Travelzoo’s calculation of non-GAAP operating income, also called “non-GAAP operating profit” in this press release and today’s earnings conference call, excludes the following items: impairment of intangibles and goodwill, amortization of intangibles, stock option expenses, and severance- related expenses. This press release includes a table which reconciles GAAP operating income to the calculation of non-GAAP operating income. Non-GAAP operating income is not required by, or presented in accordance with, generally accepted accounting principles in 
the United States of America (“GAAP”). This information should be considered as supplemental in nature and should not be considered in isolation or as a substitute for the financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similarly titled measures reported by other companies.

Looking Ahead
We currently expect higher revenue and profitability in Q2 2022. We continue to see a trend of recovery of our revenue. However, there could be unexpected fluctuations in the short term. During the pandemic, we have been able to lower our fixed costs. We believe we can keep our fixed costs relatively low in the foreseeable future—while revenue is expected to grow.

Conference Call

Travelzoo will host a conference call to discuss first quarter results and provide an update on Travelzoo META today at 
11:00 a.m. ET. Please visit http://ir.travelzoo.com/events-presentations to

  • download the management presentation (PDF format) to be discussed in the conference call; and
  • access the webcast.

About Travelzoo
Travelzoo® provides its 30 million members with exclusive offers and one-of-a-kind experiences personally reviewed by our deal experts around the globe. We have our finger on the pulse of outstanding travel, entertainment, and lifestyle experiences. We work in partnership with more than 5,000 top travel suppliers—our long-standing relationships give 
Travelzoo members access to irresistible deals.

Certain statements contained in this press release that are not historical facts may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. These forward-looking statements may include, but are not limited to, statements about our plans, objectives, expectations, prospects and intentions, markets in which we participate and other statements contained in this press release that are not historical facts. When used in this press release, the words “expect”, “predict”, “project”, “anticipate”, “believe”, “estimate”, “intend”, “plan”, “seek” and similar expressions are generally intended to identify forward-looking statements. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including changes in our plans, objectives, expectations, prospects and intentions and other factors discussed in our filings with the 
SEC. We cannot guarantee any future levels of activity, performance or achievements. 
Travelzoo undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Travelzoo, Top 20, and 
Jack’s Flight Club are registered trademarks of 
Travelzoo.

 

Travelzoo

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands, except per share amounts)
   
 

Three months ended
March 31
 

2022

  

2021

Revenues

$                 18,453

  

$                 14,284

Cost of revenues

2,832

  

3,018

          Gross profit

15,621

  

11,266

Operating expenses:

      

     Sales and marketing

8,581

  

6,790

     Product development

453

  

683

     General and administrative

4,668

  

4,560

          Total operating expenses

13,702

  

12,033

Operating income (loss)

1,919

  

(767)

Other income (loss), net

1,423

  

(166)

Income (loss) from continuing operations before income taxes

3,342

  

(933)

Income tax expense

968

  

742

Income (loss) from continuing operations

2,374

  

(1,675)

Loss from discontinued operations, net of tax

(11)

  

(15)

Net income (loss)

2,363

  

(1,690)

Net income (loss) attributable to non-controlling interest

4

  

(48)

Net income (loss) attributable to Travelzoo

$                  2,359

  

$                 (1,642)
       

Net income (loss) attributable to Travelzoo—continuing operations

$                  2,370

  

$                  (1,627)

Net loss attributable to Travelzoo—discontinued operations

$                     (11)

  

$                      (15)
       

Income (loss) per share—basic

      

     Continuing operations

$                     0.20

  

$                   (0.14)

     Discontinued operations

$                        —

  

$                         —

Net income (loss) per share —basic

$                     0.20

  

$                   (0.14)
       

Income (loss) per share—diluted

      

     Continuing operations

$                     0.19

  

$                    (0.14)

     Discontinued operations

$                        —

  

$                         —

Net income (loss) per share—diluted

$                     0.19

  

$                    (0.14)

Shares used in per share calculation from continuing operations—
basic

12,056

  

11,391

Shares used in per share calculation from discontinued operations—
basic

12,056

  

11,391

Shares used in per share calculation from continuing operations—
diluted

12,544

  

11,391

Shares used in per share calculation from discontinued operations—
diluted

12,056

  

11,391

 

Travelzoo

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands)
       
 

March 31,
2022

  

December 31,
2021

Assets

      

     Current assets:

      

          Cash and cash equivalents

$             35,617

  

$            43,815

          Accounts receivable, net

18,163

  

14,871

          Prepaid income taxes

2,547

  

3,325

          Prepaid expenses and other

1,513

  

1,891

          Prepaid expenses—related party

—

  

1,150

          Assets from discontinued operations

63

  

71

               Total current assets

57,903

  

65,123

          Deposits and other

6,588

  

6,784

          Deferred tax assets

3,887

  

3,949

          Restricted cash

1,121

  

1,142

          Operating lease right-of-use assets

6,679

  

7,700

          Property and equipment, net

572

  

659

          Intangible assets, net

5,189

  

3,426

          Goodwill

10,944

  

10,944

               Total assets

$             92,883

  

$            99,727

Liabilities and Stockholders’ Deficit

      

     Current liabilities:

      

          Accounts payable

$               3,453

  

$              3,411

          Merchant payables

60,479

  

68,678

          Accrued expenses and other

9,171

  

10,212

          Deferred revenue

2,317

  

1,733

          Operating lease liabilities

2,813

  

3,180

          Income tax payable

30

  

185

          Liabilities from discontinued operations

488

  

485

               Total current liabilities

78,751

  

87,884

          Long-term operating lease liabilities

8,617

  

9,111

          Other long-term liabilities

2,380

  

2,364

               Total liabilities

89,748

  

99,359

          Non-controlling interest

4,604

  

4,600

          Common stock

126

  

126

          Treasury stock (at cost)

(5,488)

  

(5,488)

          Additional paid-in capital

4,957

  

4,415

          Retained earnings

2,866

  

508

          Accumulated other comprehensive loss

(3,930)

  

(3,793)

               Total stockholders’ deficit

(1,469)

  

(4,232)

               Total liabilities and stockholders’ deficit

$             92,883

  

$            99,727

 

Travelzoo

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)
   
 

Three months ended
March 31
 

2022

  

2021

Cash flows from operating activities:

      

Net income (loss)

$              2,363

  

$            (1,690)

Adjustments to reconcile net income (loss) to net cash provided by (used
in) operating activities:

      

     Depreciation and amortization

574

  

484

     Stock-based compensation

541

  

882

     Deferred income tax

97

  

541

     Loss on long-lived assets

38

  

—

     Gain on sale of equity investment in WeGo

(196)

  

—

     Net foreign currency effects

(13)

  

(152)

     Reversal of reserves on accounts receivable and other reserves

(1,408)

  

(454)

     Changes in operating assets and liabilities:

      

          Accounts receivable

(3,163)

  

(2,229)

          Income tax receivable

759

  

(545)

          Prepaid expenses and other

565

  

(2,357)

          Accounts payable

103

  

1,727

          Merchant payables

(7,961)

  

13,212

          Accrued expenses and other

917

  

(641)

          Income tax payable

(157)

  

(126)

          Other liabilities

(244)

  

412

Net cash provided by (used in) operating activities

(6,764)

  

9,064

Cash flows from investing activities:

      

     Purchases of intangible assets

(1,049)

  

—

     Proceeds from sale of equity investment in WeGo

196

  

—

     Purchases of property and equipment

(89)

  

(7)

Net cash used in investing activities

(942)

  

(7)

Cash flows from financing activities:

      

     Repurchase of common stock

—

  

(1,583)

Net cash used in financing activities

—

  

(1,583)

Effect of exchange rate on cash, cash equivalents and restricted cash

(524)

  

270

Net increase (decrease) in cash, cash equivalents and restricted cash

(8,230)

  

7,744

Cash, cash equivalents and restricted cash at beginning of period

44,989

  

64,385

Cash, cash equivalents and restricted cash at end of period

$            36,759

  

$            72,129

 

Travelzoo 

Segment Information from Continuing Operations 

(Unaudited) 

(In thousands) 
                   

Three months ended
March 31, 2022

Travelzoo North

America

  

Travelzoo Europe

  

Jack’s Flight Club

  

Elimination

  

Consolidated

Revenue from unaffiliated
customers

$          11,503

  

$           6,127

  

$              823

  

$               —

  

$           18,453

Intersegment revenue

193

  

(193)

  

—

  

—

  

—

Total net revenues

11,696

  

5,934

  

823

  

—

  

18,453

Operating income

$            1,718

  

$              178

  

$                23

  

$               —

  

$             1,919
                   

Three months ended
March 31, 2021

Travelzoo North

America

  

Travelzoo Europe

  

Jack’s Flight Club

  

Elimination

  

Consolidated

Revenue from unaffiliated
customers

$            9,828

  

$           3,569

  

$              887

  

$               —

  

$           14,284

Intersegment revenue

(9)

  

9

  

—

  

—

  

—

Total net revenues

9,819

  

3,578

  

887

  

—

  

14,284

Operating income (loss)

$                 39

  

$            (696)

  

$            (110)

  

$               —

  

$               (767)

 

Travelzoo

Reconciliation of GAAP to Non-GAAP Information

(Unaudited)

(In thousands, except per share amounts)
   
 

Three months ended
March 31
 

2022

  

2021

GAAP operating expense

$             13,702

  

$             12,033

Non-GAAP adjustments:

      

     Impairment of intangible and goodwill (A)

—

  

—

     Amortization of intangibles (B)

226

  

284

     Stock option expenses (C)

541

  

882

     Severance-related expenses (D)

13

  

223

Non-GAAP operating expense

12,922

  

10,644
       

GAAP operating income (loss)

1,919

  

(767)

Non-GAAP adjustments (A through D)

780

  

1,389

Non-GAAP operating income

2,699

  

622

 

Investor Relations:
Almira Pusch
ir@travelzoo.com 

Release – Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27 2022

Posted on by Admin

 


Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022

Research, News, and Market Data on Lineage Cell Therapeutics

 

Fireside Chat with B. Riley Research Analyst Scheduled for 3:30pm Eastern Time

Topics Will Include Two New Cell Therapy Programs Launched Following Roche and Genentech Partnership for RG6501 (OpRegen®) Program

CARLSBAD, Calif.–(BUSINESS WIRE)–Apr. 26, 2022– 

Lineage Cell Therapeutics, Inc.
 (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today  Brian M. Culley, Lineage’s Chief Executive Officer, will present at the B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference, in a fireside chat hosted by  Mayank Mamtani, Managing Director, Senior Biotech Research Analyst and Group Head of Healthcare Research at 
B. Riley Securities, on 
Wednesday April 27th, 2022 at 
3:30pm EST.

Interested parties can register to view both the live event and replay on the Events and Presentations section of Lineage’s website. Additional videos are available on the Media page of the Lineage website.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include five allogeneic (“off-the-shelf”) product candidates: (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, which is now being developed under a worldwide collaboration with Roche and
Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy, and (v) PNC1, a photoreceptor neural cell therapy for the treatment of vision loss due to photoreceptor dysfunction or damage. For more information, please visit www.lineagecell.com or follow the company on Twitter @LineageCell.

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(ir@lineagecell.com)
(442) 287-8963

Solebury Trout IR
Mike Biega
(Mbiega@soleburytrout.com)
(617) 221-9660

|Russo Partners – Media Relations
Nic Johnson or  David Schull
Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com
(212) 845-4242

Source: 
Lineage Cell Therapeutics, Inc.

Release – electroCore Completes Sale of New Jersey Tax Benefits

Posted on by Admin



electroCore Completes Sale of New Jersey Tax Benefits

News and Market Data on electroCore

 

ROCKAWAY, N.J., 
April 26, 2022 (GLOBE NEWSWIRE) — 
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has completed the sale of its available tax benefits through the New Jersey Economic Development Authority’s Technology Business Tax Certificate Transfer program for fiscal year 2021. As a result, the Company has received approximately 
$445,000 in non-dilutive cash from the sale of these net operating loss (NOL) tax benefits.

“We are pleased to have received 
$445,000 from the New Jersey NOL program,” commented  Brian Posner, Chief Financial Officer of electroCore. “This is the third consecutive year that we have benefited from this program which provides us non-dilutive funding that will be beneficial to us as we continue to invest in our sales channels and marketing initiatives to expand consumer awareness of gammaCore.”

The New Jersey Technology Business Tax Certificate Transfer program enables qualified, unprofitable NJ-based technology or biotechnology companies with fewer than 225 US employees (including parent company and all subsidiaries) to sell a percentage of their NOL and research and development tax credits to unrelated profitable corporations. NOLs may be sold for at least 80 percent of their value, up to a maximum lifetime benefit of 
$20 million per business. This allows qualifying technology and biotechnology companies with NOLs to turn tax losses and credits into cash proceeds to fund their growth and operations, including research and development or other allowable expenditures.

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.

For more information, visit www.electrocore.com.

About gammaCore™
gammaCore™ (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore is self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients.

gammaCore (nVNS) is FDA cleared in 
the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients, and paroxysmal hemicrania and hemicrania continua in adult patients. gammaCore is CE-marked in the 
European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

gammaCore is contraindicated for patients if they:

  • Have an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
  • Have a metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
  • Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)

Safety and efficacy of gammaCore have not been evaluated in the following patients:

  • Adolescent patients with congenital cardiac issues
  • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
  • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
  • Pediatric patients (less than 12 years)
  • Pregnant women
  • Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

For more information, please visit gammaCore.com

Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding electroCore’s business prospects, its sales and marketing and product development plans, future cash flow projections, anticipated costs, its product portfolio or potential markets for its technologies, the availability and impact of payor coverage, the potential of nVNS generally and gammaCore in particular to treat COVID-19, and other statements that are not historical in nature, particularly those using terminology such as “anticipates,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore’s business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize gammaCore™, competition in the industry in which electroCore operates and general market conditions. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the
SEC, available at www.sec.gov.

Contact:
Rich Cockrell

CG Capital
404-736-3838
ecor@cg.capital

Release – QuoteMedia Announces Major Agreement with a Schedule 1 Canadian Bank

Posted on by Admin



QuoteMedia Announces Major Agreement with a Schedule 1 Canadian Bank

Research, News, and Market Data on QuoteMedia

 

PHOENIX, April 26, 2022 (GLOBE NEWSWIRE) — QuoteMedia, Inc. (OTCQB: QMCI), a leading provider of market data and financial applications, announced that it has been selected as market data and technology provider for one of the Schedule 1 Canadian banks.

Pursuant to the multi-year agreement, QuoteMedia will provide a wide-ranging enterprise deployment of financial data solutions for hundreds of thousands of the bank’s trading customers, including a new fully responsive quotes and research portal that is designed to be compliant with all applicable accessibility requirements. QuoteMedia will also be providing custom mobile solutions, and Quotestream TM Web, QuoteMedia’s HTML5 portfolio management and trading platform. All of these services are powered by QuoteMedia’s comprehensive data offerings.

“There is a significant demand among retail investors, particularly among high net-worth investors and those who trade frequently, for newer and more sophisticated data and technology solutions to support their investing decisions,” said Dave Shworan, CEO of QuoteMedia Ltd. “We are very pleased to have been chosen by one of the largest banks in Canada to provide comprehensive data solutions, along with our industry leading technologies, to ensure their customers have the in-depth and up-to-date information and tools they need for research, trading and managing their portfolios.

“This agreement is a major victory for QuoteMedia and is another confirmation of the strategies we have employed in building our company.”

About QuoteMedia

QuoteMedia is a leading software developer and cloud-based syndicator of financial market information and streaming financial data solutions to media, corporations, online brokerages, and financial services companies. The Company licenses interactive stock research tools such as streaming real-time quotes, market research, news, charting, option chains, filings, corporate financials, insider reports, market indices, portfolio management systems, and data feeds. QuoteMedia provides industry leading market data solutions and financial services for companies such as the Nasdaq Stock Exchange, TMX Group (TSX Stock Exchange), Canadian Securities Exchange (CSE), London Stock Exchange Group, FIS, U.S. Bank, Broadridge Financial Systems, JPMorgan Chase, CI Financial, Canaccord Genuity Corp., Hilltop Securities, HD Vest, Stockhouse, Zacks Investment Research, General Electric, Boeing, Bombardier, Telus International, Business Wire, PR Newswire, FolioFN, Regal Securities, ChoiceTrade, Cetera Financial Group, Dynamic Trend, Inc., Qtrade Financial, CNW Group, IA Private Wealth, Ally Invest, Inc., Suncor, Virtual Brokers, Leede Jones Gable, Firstrade Securities, Charles Schwab, First Financial, Cirano, Equisolve, Stock-Trak, Mergent, Cision, Day Trade Dash, LLC and others. Quotestream®, QMod TM and Quotestream Connect TM are trademarks of QuoteMedia. For more information, please visit www.quotemedia.com.

Statements about QuoteMedia’s future expectations, including future revenue, earnings, and transactions, as well as all other statements in this press release other than historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. QuoteMedia intends that such forward-looking statements be subject to the safe harbors created thereby. These statements involve risks and uncertainties that are identified from time to time in the Company’s SEC reports and filings and are subject to change at any time. QuoteMedia’s actual results and other corporate developments could differ materially from that which has been anticipated in such statements.

QuoteMedia Investor Relations
Brendan Hopkins
Email: investors@quotemedia.com
Call: (407) 645-5295

PTSD MDMA and Psilocybin

Posted on by Admin 


Image Credit: Peter Murphy (Flickr)


Latest Trials Confirm the Benefits of MDMA – the Drug in Ecstasy – for Treating PTSD

 

For people with post-traumatic stress disorder, recalling memories of physical or sexual assault, combat or disaster-related events can induce intense anxiety or panic attacks as well as debilitating flashbacks.

In the U.S., about 7% of people suffer from PTSD and lose an average of about four working days each month as a result. Trauma-specific psychotherapy, like cognitive processing or “talk” therapy, is the cornerstone of treatment for PTSD. But for approximately half of people, these traditional approaches are ineffective at fully addressing PTSD symptoms over the long term. Antidepressant drugs are frequently used if psychotherapy fails, or in combination with it, but the effects are usually modest.

MDMA (3,4-methylenedioxymethamphetamine) is an active ingredient in the illicit street drug known as ecstasy or molly. People in dance clubs and raves use illicit MDMA because it elevates mood and energy levels, induces a feeling of bonding with others and produces a surreal psychedelic effect. These same effects have been hypothesized to support people with PTSD during psychotherapy sessions, since they can make people more willing and able to share and explore their traumatic experiences. Our new meta-analysis of clinical trials confirms the benefits of MDMA-assisted psychotherapy in the treatment of PTSD.

 

This article was republished with permission from The Conversation, a news site dedicated to sharing ideas from academic experts. It was written by and represents the research-based opinions of C. Michael White, Distinguished Professor and Head of the Department of Pharmacy Practice, University of Connecticut. Adrian V. Hernandez, Associate Professor of Comparative Effectiveness and Outcomes Research, University of Connecticut.

 

We are a pharmacist and physician team who investigate the benefits and harms associated with substances of abuse like bath salts, phenibut, cannabis and synthetic marijuana. Through this work we have become intrigued about the therapeutic potential for some psychedelic drugs in the treatment of myriad psychiatric disorders, from PTSD to major depression, especially MDMA and psilocybin (hallucinogenic mushrooms).

It is important to state that using ecstasy or molly products from the street would not help PTSD symptoms because the MDMA needs be used along with carefully crafted psychotherapy in a safe, controlled environment. Ecstasy or molly products purchased illicitly never specify the exact amount of MDMA they contain, so it is impossible to dose it properly for PTSD. Taking too much MDMA or exercising while taking MDMA can cause heart attacks, strokes, seizures and arrhythmias and can damage muscles and kidneys.

 

What is MDMA-Assisted Psychotherapy?

In an MDMA-assisted psychotherapy session, patients take MDMA as a pill upon entering a psychiatrist’s office and then work with a team of therapists who help them divulge traumatic events or discuss aspects of those events over the course of several hours. They usually have non-MDMA sessions before the first MDMA session so they know what to expect. And they have at least one non-MDMA session after each MDMA one to work through the traumatic memories that were revealed and to learn coping strategies. A standard treatment course includes two or three multi-hour MDMA-assisted psychotherapy sessions and several non-MDMA sessions.

The MDMA products used in these sessions are pharmaceutical grade. This means that, unlike illicitly obtained street products, they do not contain other substances of abuse, such as methamphetamine, or contaminants like heavy metals, bacteria or mold. People with hypertension or those at high risk of heart attacks, strokes or arrhythmias should not participate, because they can have unsafe elevations in blood pressure and heart rate. In addition, patients are not allowed to leave for eight hours, until the effects of MDMA have fully worn off.


Assessing the Effectiveness of MDMA-Assisted Psychotherapy

In 2014, we reviewed the available animal data and the few preliminary human studies of MDMA-assisted psychotherapy, but at the time, higher-quality clinical trials had not yet been completed. But in the past few years, larger and higher-quality trials have been published, warranting an in-depth assessment.

So we recently reviewed the data comparing antidepressant use to placebos for patients with PTSD and performed a meta-analysis study of the six different clinical trials that assessed the usefulness of MDMA-assisted psychotherapy versus psychotherapy alone. All of the trials we analyzed included both men and women who had experienced a multitude of traumatic events that led to PTSD. The studies used the same points scale to determine the effectiveness of therapy, making it easier to compare data across studies. Scores above approximately 50 points mean a patient has severe PTSD, and scores reduced by more than 10 points from baseline are clinically meaningful.

We found that daily antidepressant therapy reduced PTSD by 6 to 14 points compared with the placebo, but a range of 27% to 47% of patients across the studies withdrew before the end of the trials. In contrast, MDMA-assisted psychotherapy reduced the scores by 22 points compared with those receiving psychotherapy with placebo, and patients were twice as likely to no longer meet the criteria for PTSD diagnosis by the end of the trials. In addition, only 8% of patients withdrew from MDMA-assisted psychotherapy trials. The main adverse effects included teeth grinding, jitteriness, headache and nausea. One of these MDMA trials found that participants’ blood pressure and heart rate were elevated in the course of MDMA therapy, but not to a concerning extent.

For several of the trials in our meta-analysis, investigators sent a questionnaire to participants 12 months after their last MDMA session to assess the long-term impact. Overall, 86% of participants said they received substantial benefits from the combined MDMA-assisted psychotherapy. Eighty-four percent of participants reported having improved feelings of well-being, 71% had fewer nightmares, 69% had less anxiety and 66% had improved sleep. The results from across all of the studies suggested that MDMA-assisted therapy was helping to alleviate the PTSD itself, not simply suppressing symptoms.

 

Looking Ahead

The U.S. Drug Enforcement Administration identifies MDMA and psilocybin as Schedule I controlled substances. According to the DEA, these substances have no currently accepted medical use in the U.S. and come with high abuse potential.

However, it’s worth noting an important exception. Cannabadiol, or CBD, a chemical that comes from the plant Cannabis sativa, is classified as a Schedule I drug. But the Food and Drug Administration approved its use in 2018 for the treatment of two rare and severe childhood seizure disorders. That doesn’t mean that the CBD in your lotion or seltzer has proof of benefit for most of the ills people are using it for, but its full therapeutic potential is still being explored. Given the strong consistent beneficial effects and manageable adverse events in the newer trials designed with FDA input, we suspect that MDMA-assisted psychotherapy will become an FDA-approved option for PTSD by the end of 2023. Psilocybin – commonly known as hallucinogenic mushrooms – also shows promise for treating major depression, but further research is needed.

The DEA’s stringent policies made it exceptionally hard for scientists to conduct research on Schedule I drugs for decades by criminalizing the possession of the products, even in research settings. But in 2018, the agency streamlined the application process for securing a waiver for research purposes. This made it easier for researchers to conduct trials into the pharmaceutical value of psychedelic drugs. Within the next decade, this shift will almost certainly accelerate the discovery of new treatments for patients suffering from mental illness.

 

Suggested Content



Psychedelic Medicine a Revolution for the Mind

Psychedelic Laws and Investments May Follow Cannabis’ Success





Acceptance of Psychedelics for Wellness and Recreation

Psychedelics, the Next Breakthrough in Mental Health Treatment (Video)

 

Stay up to date. Follow us:

 

Bowlero (BOWL) – A Sanguine Outlook

Posted on by Admin

Tuesday, April 26, 2022

Bowlero (BOWL)
A Sanguine Outlook

Bowlero Corp. is the worldwide leader in bowling entertainment. With more than 300 bowling centers across North America, Bowlero Corp. serves more than 26 million guests each year through a family of brands that includes Bowlero, Bowlmor Lanes, and AMF. Bowlero Corp. is also home to the Professional Bowlers Association, which it acquired in 2019 and which boasts thousands of members and millions of fans across the globe. For more information on Bowlero Corp., please visit BowleroCorp.com.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Patrick McCann, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Noblecon 18 highlights.  Tom Shannon, CEO, provided a compelling update on the company’s recent success and planned developments. Some of the topics discussed include: the company’s compelling roll-up strategy, inflationary effects, continued COVID recovery, cost reductions, and the upcoming beta testing of new in-center features. The full video of the presentation can be found here.

    COVID recovery still a boost.  Bowlero experienced a favorable revenue rebound as the country emerged from lockdowns, with revenue growth 177% year-over-year in the most recent quarter. Those results, however, did not reflect a full recovery. Notably, the retail and event-driven businesses are now rebounding in locations like New York. This rebound could lead toward positive upside revenue and …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Kelly Services (KELYA) – NobleCon 18 Presentation

Posted on by Admin

Tuesday, April 26, 2022

Kelly Services (KELYA)
NobleCon 18 Presentation

Kelly Services Inc is a provider of workforce solutions and consulting and staffing services. The company’s operations are divided into three business segments namely Americas Staffing, Global Talent Solutions (“GTS”) and International Staffing. It provides staffing solutions through its branch networks in Americas and International operations and also provides a suite of innovative talent fulfilment and outcome-based solutions through GTS segment. Americas Staffing generates maximum revenue from its operations.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    NobleCon 18. Kelly Services CEO Peter Quigley and CFO Olivier Thirot presented at NobleCon 18. Highlights of the presentation were the recent Persol Holdings and PersolKelly sales, the RocketPower acquisition, and strategy for future acquisitions. A rebroadcast is available here.

    More Cash in the Pocket.  The Company highlighted their recent sale of Persol Holdings common shares and PersolKelly joint venture interest. Both these sales accumulated roughly $235 million, net of repurchases of common shares. This additional cash will prove to be beneficial, in our view, as the Company is aggressively looking for companies to purchase …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

RCI Hospitality (RICK) – NobleCon 18 Presentation

Posted on by Admin

Tuesday, April 26, 2022

RCI Hospitality (RICK)
NobleCon 18 Presentation

RCI Hospitality Holdings, Inc. through its subsidiaries owns and operates establishments that offer live adult entertainment, restaurant, and/or bar operations. The company also owns and operates a communication company serving the adult nightclubs industry. RCI’s operating business segments includes Nightclubs and Bombshells restaurants and bars. It operates nightclubs through the following brands: Rick’s Cabaret, Vivid Cabaret, Tootsie’s Cabaret, Club Onyx, and Jaguars Club. In the restaurants segment, the company is building a chain of Bombshells Restaurants and Sports Bars in Dallas, Austin, and Houston, Texas.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    NobleCon 18. RCI CEO Eric Langan presented at NobleCon 18. The Company highlighted its strategy of building a portfolio of well managed, high cash flowing nightclubs and restaurants. A rebroadcast is available here.

    Portfolio of Hospitality Venues.  RCI has built a strong portfolio of 49 Gentlemen’s Clubs across 13 states and 11 Bombshells restaurants. These business feature strong cash generation, real estate ownership, and barriers to entry, specifically in the Gentlemen’s Clubs segment …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.